

Powered by
UBS Evidence Lab

US Semiconductors/Semi Equipment

UBS Evidence Lab inside: Employee Sentiment Monitor – NVDA and INTC Lead, MU Lags

Employee Satisfaction at 5-year high despite Business outlook having peaked

We utilize UBS Evidence Lab's analysis of Glassdoor data to see trends in active employee sentiment among major US-based semis and SPE companies. In aggregate, the data shows consistent improvement in overall satisfaction across the industry over the past 5yrs with particularly strong improvement at AMD and NVDA. Employees at INTC have also become notably more optimistic, particularly around business outlook (somewhat surprising given the manufacturing challenges) and CEO change. On the other hand, overall satisfaction at MU has declined over the period and is the worst among the cohort. Among semi equipment companies, satisfaction is the highest at LRCX with significant recovery from last year, maybe related to CEO changes.

Business outlook – AMD leading, NVDA remains consistently high

Employees are most optimistic about overall business prospects at AMD – a strong validation of CEO Lisa Su's leadership and competitive positioning. Scores at NVDA have remained consistently very high for the past several years and employees have, over the past 3yrs, become quite bullish about MRVL's prospects given new leadership and a host of strategic changes/M&A. Despite legal challenges, QCOM has seen some steady improvement ahead of 5G while the outlook among employees at AVGO has declined materially over the past several years (potentially due to internal uncertainty given its ongoing M&A strategy). Business outlook has deteriorated for semicaps in general (likely due in part to the recent memory cycle), but AMAT saw a particularly big decline this year. TXN's employee ratings remains solid and very consistent.

CEO Approval – AMD, NVDA on top but INTC improving

AMD and NVDA (we remain v bullish) enjoy the highest CEO ratings w/ >95% approving. AVGO is lowest on an absolute basis (though again, likely M&A related) followed by MU. Approval of Steve Mollenkopf at QCOM improved considerably this year as it struck the deal with AAPL and works through the legal appeal of the FTC verdict. Despite 10nm challenges, CEO approval at INTC climbed considerably this year while approval at AMAT dropped considerably to now more middle-of-the-pack.

Longer-term observations

AI has transformed employee bullishness at NVDA, AMD appears to have considerable staying power, and MRVL has improved along all dimensions with new management.

Equities

Global
Semiconductors

Timothy Arcuri

Analyst

timothy.arcuri@ubs.com
+1-415-352 5676

Pradeep Ramani

Analyst

pradeep.ramani@ubs.com
+1-415-352 5517

每日免费获取报告

1. 每日微信群内分享7+最新重磅报告；
2. 定期分享华尔街日报、金融时报、经济学人；
3. 和群成员切磋交流，对接优质合作资源；
4. 累计解锁8万+行业报告/案例，7000+工具/模板

申明：行业报告均为公开版，权利归原作者所有，小编整理自互联网，仅分发做内部学习。

截屏本页，微信扫一扫
或搜索公众号“尖峰报告”
回复<进群>，加入微信群

限时赠送“2019行业资料大礼包”，关注即可获取



Highlights from the UBS Evidence Lab Employee Survey

Which companies in the US Semiconductor industry lead and lag based on Employee Satisfaction and CEO Approval? UBS Evidence Lab has collected more than 3MM employee reviews across 7000+ distinct employers to help answer this question. We interpret the results from the UBS Evidence Lab survey.

NVDA ranks highest, MU lowest in aggregate

UBS Evidence Lab looked at several major evaluation criteria including career opportunities, compensation/benefits, work/life balance, senior management/CEO, culture/values, and overall business outlook. The project also looked at how likely employees were to recommend the employer to a friend. Taking the current snapshot of ratings from employees, we see NVDA with the highest overall employee satisfaction ranking very high across the board on all factors. Somewhat surprisingly, given all of the issues around manufacturing, INTC ranks second overall. On the other hand, MU ranks last overall due to such factors as senior management and culture/values (though we note some of this is likely due to potential uncertainty given leadership changes over the past few years and the overall memory cycle).

Figure 1: Ranking of major semis and SPE companies

	Overall	Career Opportunities	Compensation & Benefits	Work Life Balance	Senior Management	Culture Values	Business Outlook	CEO Approval	Recommend to a Friend
Nvidia	4.50	4.33	4.34	4.05	4.23	4.44	92%	95%	94%
Intel	4.30	4.10	4.19	4.15	3.77	4.25	81%	79%	89%
Texas Instruments	4.11	3.86	3.93	3.70	3.61	4.10	83%	87%	81%
AMD	4.10	3.94	3.39	4.04	3.68	4.09	94%	95%	88%
Qualcomm	3.93	3.72	3.83	3.52	3.26	3.76	75%	73%	79%
Marvell Technology Group	3.90	3.48	3.68	3.91	3.76	4.05	76%	90%	78%
Lam Research	3.88	3.56	4.03	3.37	3.37	3.91	75%	78%	78%
Broadcom	3.73	3.31	4.00	3.93	3.05	3.53	52%	52%	62%
Applied Materials	3.67	3.38	3.52	3.32	3.24	3.42	64%	71%	67%
KLA Corp	3.66	3.12	3.33	3.19	3.32	3.59	73%	72%	76%
Micron Technology	3.37	3.33	3.76	2.95	2.85	3.17	60%	58%	60%

Source: UBS Evidence Lab, Glassdoor

Overall employee satisfaction in semis at 5yr highs even as the perception is that business prospections have peaked

We then looked at the numbers over time, focusing on the past 5yrs to see notable changes. Overall employee satisfaction scores in Semis have been steadily improving since 2014 (with 2018 being the only exception) and have reached 5yr highs in 2019 (average score of 3.92 in 2019 vs. 3.52 in 2014). Underneath the hood, every company in Figure 1 has improved its score over the 5yr period, with NVDA leading the group on overall satisfaction (also the top scoring company in our large cap technology peer group).


Figure 2: Overall Employee Satisfaction

Entity	Period					
	2014	2015	2016	2017	2018	2019
AMD	3.18	3.24	3.75	3.76	3.97	4.10
Applied Materials	3.36	3.59	3.65	3.60	3.89	3.67
Broadcom	3.41	3.43	3.55	3.68	3.69	3.73
Intel	3.87	3.82	3.72	3.90	3.92	4.30
KLA Corp	3.20	3.42	3.69	3.72	3.81	3.66
Lam Research	3.51	3.83	3.85	4.02	3.56	3.88
Marvell Technology Group	3.28	3.39	3.66	4.02	3.75	3.90
Micron Technology	3.45	3.51	3.52	3.63	3.52	3.37
Nvidia	3.82	3.92	4.14	4.51	4.49	4.50
Qualcomm	3.94	3.56	3.63	3.82	3.75	3.93
Texas Instruments	3.74	3.83	4.01	3.97	4.01	4.11
Average	3.52	3.59	3.74	3.88	3.85	3.92

Source: UBS Evidence Lab, Glassdoor

Notable positive movers over the past 5yrs are AMD – expected and logical given Lisa Su's appointment and clearly better direction now for the company, NVDA as its prospects continue to improve, and AMAT – in part due to CEO Gary Dickerson's direction (our view).

Figure 3: Overall Employee Satisfaction



Source: UBS Evidence Lab, Glassdoor

Source: UBS Evidence Lab, Glassdoor

Business outlook

When we break this down a little further into each factor, we see that the perception around business outlook for semis in aggregate seems to have peaked in 2017 (on average) although employees at NVDA and AMD are far more bullish about the company's prospects than at other companies. Interestingly, despite all of its recent issues around manufacturing, employees at INTC remain reasonably optimistic about its business prospects.

On the other hand, employees at MU and AVGO have become much more bearish about the overall prospects of the company in recent years but some of this could be due to the substantial changes each has undergone over the period.


Figure 4: Business Outlook Perception appears to have peaked

Entity	Period					
	2014	2015	2016	2017	2018	2019
AMD	0.43	0.38	0.66	0.79	0.89	0.94
Applied Materials	0.70	0.70	0.83	0.87	0.84	0.64
Broadcom	0.56	0.58	0.64	0.61	0.54	0.52
Intel	0.65	0.73	0.62	0.75	0.78	0.81
KLA Corp	0.63	0.53	0.77	0.86	0.77	0.73
Lam Research	0.81	0.87	0.88	0.89	0.72	0.75
Marvell Technology Group	0.63	0.52	0.54	0.84	0.76	0.76
Micron Technology	0.80	0.70	0.58	0.82	0.75	0.60
Nvidia	0.75	0.83	0.92	0.95	0.93	0.92
Qualcomm	0.77	0.46	0.66	0.69	0.57	0.75
Texas Instruments	0.64	0.80	0.87	0.85	0.87	0.83
Average	0.67	0.65	0.72	0.81	0.76	0.75

Source: UBS Evidence Lab, Glassdoor

Interestingly, AMD has gone from ranking last in overall business outlook to now ranking the best in our peer group.

Figure 5: Business Outlook change 2014-2019



Source: UBS Evidence Lab, Glassdoor


Source: UBS Evidence Lab, Glassdoor

We think that as product cycles at both NVDA (RTX,Ampere) and AMD (Rome, Ryzen) ramp and with INTC Ice Lake still expected in H2:2020 employee perception the general business outlook on average (>90% of employees surveyed for AMD/NVDA) seems more positive than in the rest of semis.

On the other hand, the memory industry is still working through the cycle and we think this largely explains MU's scores (60%) at the lower end. With memory likely to bottom in early/mid 2020, we are expecting MU's scores to start inflecting higher as we work through the cycle.

With AVGO working through M&A integration and with AVGO indicating its longer-term intention to focus on capital allocation (which we think could include dividends, repos and more M&A), we think this could be one factor that potentially depresses AVGO employee Business outlook perception scores (52%).

Figure 6: General Business Outlook



Source: UBS Evidence Lab, Glassdoor

Source: UBS Evidence Lab, Glassdoor


On a relative basis (2018 vs. 2019) QCOM's scores have shown the largest improvement (from 57% in 2018 to 75% in 2019), we think this increase makes sense directionally given that QCOM is making progress on the litigation front and is highly levered to the 5G that is only just beginning to ramp worldwide. TXN is working through the inventory/macro cycle, but TXN's largest customer still only accounts for <1% of revs, meaning TXN's diversified product portfolio/customer base is helping it weather the storm and we think that somewhat explains a slight deterioration of its scores from 87% in 2018 to 83% in 2019.

CEO Approval

On an absolute basis, NVDA and AMD CEO's enjoy the highest approval ratings (~95% of the employees taking the survey approve), with QCOM showing the largest Y/Y improvement in score. This somewhat mirrors the favorable business outlook survey results but is a bit surprising on QCOM given the ongoing legal challenges and FTC appeal.

Similarly, MU and AVGO approvals are lagging, but again we think this can be explained by the memory cycle (which should turn early CY2020) and AVGO working through M&A integration.

Figure 7: CEO Approval



Source: UBS Evidence Lab, Glassdoor


Source: UBS Evidence Lab, Glassdoor

Some other interesting comparisons

AMD vs. INTC

With AMD gaining momentum/share in all segments (Server, Mobile, PC), AMD's CEO ratings remain highly favorable. Interestingly, for INTC on the other hand, post appointment of Bob Swan as CEO, despite INTC's process challenges, CEO approval ratings have recovered and are north of 80%, meaning his strategy to transition INTC towards a more data centric company seems to be favorably reflected in our survey.


Figure 8: INTC vs. AMD



Source: UBS Evidence Lab, Glassdoor

Source: UBS Evidence Lab, Glassdoor

Figure 9: NVDA vs. INTC vs. AMD




Source: UBS Evidence Lab, Glassdoor

Source: UBS Evidence Lab, Glassdoor

LRCX scores highest among SPE companies across most dimensions

LRCX scores higher than AMAT/KLAC on all dimensions, including CEO approval and compensations/benefits, although all three companies saw a decline among employees in the perception around the CEO in the past year.

Figure 10: AMAT vs. KLAC vs. LRCX



Source: UBS Evidence Lab, Glassdoor


Source: UBS Evidence Lab, Glassdoor

Overall ratings at LRCX reflect recent changes

Overall employee satisfaction declined materially during the time preceding the CEO change on 6/24/18 and have since steadily recovered since Tim Archer was appointed. Ratings are now back close to their historic highs at LRCX while KLAC has been more consistent over time given the long tenure now of Rick Wallace.


LRCX does score materially better than KLAC on factors such as career opportunities and compensation/benefits.

Figure 11: KLAC vs. LRCX (Overall)



Source: UBS Evidence Lab, Glassdoor


Figure 12: KLA vs. LRCX (Business Outlook)



Source: UBS Evidence Lab, Glassdoor

Source: UBS Evidence Lab, Glassdoor


Figure 13: KLAC vs. LRCX (Compensation/Benefits)



Source: UBS Evidence Lab, Glassdoor

Source: UBS Evidence Lab, Glassdoor


Figure 14: KLA vs. LRCX (Career Opportunities)



Source: UBS Evidence Lab, Glassdoor

Source: UBS Evidence Lab, Glassdoor

Figure 15: KLA vs. LRCX (Culture Values)



Source: UBS Evidence Lab, Glassdoor


Source: UBS Evidence Lab, Glassdoor

Longer-Term View

NVDA, MRVL, TXN showing improvement across multitude of vectors

Taking a longer-term view, our survey results demonstrate that NVDA has shown improvement across all vectors (on an absolute basis). With the AI wave transforming NVDA over the last 5yrs, survey shows business outlook scores are much higher now (4.62 in 2019 vs. 3.77 in 2014) with NVDA scores 4.50 overall (vs. 3.82 in 2014). Survey results also show that NVDA's improved Busienss outlook is being reflected in Employee Compensation/Benefits score expanding from 3.540 to 4.34 over the 5yr period. On a relative basis (see comparison with INTC, AMD) NVDA still has the highest overall scores.

Figure 16: NVDA has shown improvement across all vectors




Source: UBS Evidence Lab, Glassdoor

Source: UBS Evidence Lab, Glassdoor

We have had a generally favorable view of the transformation underway at MRVL, and survey results indicate that the company has indeed improved along most dimensions since the new management team took over. Notably both CEO approval and Senior Management scores have expanded over this period from 3.15 to 4.52 and 2.91 to 3.76, respectively.


Figure 17: MRVL scores have shown broad-based improvement since the new mgmt team took over in 2016



Source: UBS Evidence Lab, Glassdoor

Source: UBS Evidence Lab, Glassdoor

Figure 18: TXN shows improvement along a multitude of vectors



Source: UBS Evidence Lab, Glassdoor

Source: UBS Evidence Lab, Glassdoor

We show below the historical numbers for each of the metrics not shown above.

Figure 19: Career opportunities

Career Opportunities

Entity	Period					
	2014	2015	2016	2017	2018	2019
AMD	3.01	2.91	3.50	3.50	3.74	3.94
Applied Materials	3.28	3.18	3.28	3.38	3.61	3.38
Broadcom	3.16	3.07	3.18	3.27	3.32	3.31
Intel	3.54	3.49	3.50	3.64	3.65	4.10
KLA Corp	3.02	3.07	3.25	3.24	3.44	3.12
Lam Research	3.26	3.56	3.48	3.67	3.31	3.56
Marvell Technology Group	3.04	3.16	3.54	3.81	3.68	3.48
Micron Technology	3.13	3.18	3.35	3.39	3.34	3.33
Nvidia	3.63	3.63	3.89	4.29	4.34	4.33
Qualcomm	3.70	3.27	3.38	3.65	3.48	3.72
Texas Instruments	3.47	3.63	3.72	3.74	3.92	3.86
Average	3.29	3.28	3.46	3.60	3.62	3.65

Source: UBS Evidence Lab, Glassdoor

Figure 20: Compensation and benefits

Compensation & Benefits		Period					
Entity		2014	2015	2016	2017	2018	2019
AMD		3.26	3.15	3.34	3.27	3.38	3.39
Applied Materials		3.51	3.52	3.47	3.48	3.88	3.52
Broadcom		3.56	3.58	3.72	3.88	3.90	4.00
Intel		3.90	3.76	3.86	3.85	3.82	4.19
KLA Corp		3.24	3.29	3.46	3.33	3.62	3.33
Lam Research		3.54	3.70	3.88	3.83	3.66	4.03
Marvell Technology Group		2.90	3.11	3.36	3.49	3.70	3.68
Micron Technology		3.69	3.47	3.57	3.67	3.80	3.76
Nvidia		3.50	3.68	3.84	4.35	4.26	4.34
Qualcomm		3.94	3.69	3.51	3.67	3.80	3.83
Texas Instruments		3.81	3.89	4.06	3.85	3.87	3.93
Average		3.53	3.53	3.64	3.70	3.79	3.82

Source: UBS Evidence Lab, Glassdoor

Figure 21: Work/life balance

Work Life Balance		Period					
Entity		2014	2015	2016	2017	2018	2019
AMD		3.46	3.54	3.93	3.73	4.13	4.04
Applied Materials		3.03	3.29	3.35	3.41	3.37	3.32
Broadcom		3.64	3.58	3.69	3.81	3.91	3.93
Intel		3.79	3.66	3.66	3.79	3.89	4.15
KLA Corp		2.91	3.01	3.25	3.52	3.50	3.19
Lam Research		2.92	3.10	3.19	3.21	3.27	3.37
Marvell Technology Group		3.23	3.17	3.76	3.81	4.00	3.91
Micron Technology		3.33	3.34	3.31	3.22	3.10	2.95
Nvidia		3.18	3.41	3.61	3.93	3.93	4.05
Qualcomm		3.40	3.15	3.21	3.49	3.42	3.52
Texas Instruments		3.65	3.57	3.66	3.71	3.56	3.70
Average		3.32	3.35	3.51	3.61	3.64	3.65

Source: UBS Evidence Lab, Glassdoor

Figure 22: Senior management

Senior Management		Period					
Entity		2014	2015	2016	2017	2018	2019
AMD		2.72	2.59	3.12	3.17	3.49	3.68
Applied Materials		2.78	3.10	3.17	3.20	3.33	3.24
Broadcom		2.81	2.83	2.98	3.11	3.01	3.05
Intel		3.21	3.25	2.98	3.19	3.30	3.77
KLA Corp		3.02	3.03	3.23	3.24	3.53	3.32
Lam Research		3.38	3.25	3.33	3.44	2.98	3.37
Marvell Technology Group		2.56	2.91	2.91	3.74	3.49	3.76
Micron Technology		3.05	3.16	2.98	3.14	2.89	2.85
Nvidia		3.22	3.57	3.79	4.24	4.14	4.23
Qualcomm		3.42	2.87	2.95	3.20	2.95	3.26
Texas Instruments		3.06	3.41	3.58	3.52	3.62	3.61
Average		3.02	3.09	3.18	3.38	3.34	3.47

Source: UBS Evidence Lab, Glassdoor

Figure 23: Culture/values

Culture Values		Period					
Entity		2014	2015	2016	2017	2018	2019
AMD		3.29	3.14	3.65	3.44	3.94	4.09
Applied Materials		3.12	3.46	3.56	3.46	3.62	3.42
Broadcom		3.39	3.37	3.42	3.53	3.62	3.53
Intel		3.56	3.53	3.59	3.75	3.75	3.93
KLA Corp		3.82	3.76	3.64	3.81	3.86	4.25
Lam Research		2.98	3.32	3.54	3.53	3.92	3.59
Marvell Technology Group		3.54	3.64	3.86	3.86	3.37	3.91
Micron Technology		2.93	3.00	3.43	3.70	3.83	4.05
Nvidia		3.50	3.50	3.34	3.46	3.28	3.17
Qualcomm		3.75	3.89	4.04	4.44	4.39	4.44
Texas Instruments		3.68	3.38	3.41	3.54	3.50	3.76
Average		3.76	3.84	4.12	4.08	3.99	4.10
		3.44	3.49	3.63	3.72	3.76	3.85

Source: UBS Evidence Lab, Glassdoor

Figure 24: CEO approval

CEO Approval

Entity	Period					
	2014	2015	2016	2017	2018	2019
AMD	0.61	0.67	0.80	0.81	0.94	0.95
Applied Materials	0.72	0.65	0.76	0.73	0.83	0.71
Broadcom	0.58	0.61	0.66	0.69	0.58	0.52
Intel	0.75	0.76	0.59	0.69	0.69	0.79
KLA Corp	0.70	0.74	0.79	0.76	0.79	0.72
Lam Research	0.82	0.86	0.88	0.84	0.82	0.78
Marvell Technology Group	0.55	0.63	0.63	0.91	0.85	0.90
Micron Technology	0.75	0.77	0.72	0.75	0.69	0.58
Nvidia	0.89	0.88	0.92	0.97	0.95	0.95
Qualcomm	0.84	0.54	0.64	0.71	0.49	0.73
Texas Instruments	0.65	0.80	0.85	0.85	0.83	0.87
Average	0.71	0.72	0.75	0.79	0.77	0.77

Source: UBS Evidence Lab, Glassdoor

Figure 25: Methodology

Methodology

Overview

Glassdoor is a leading careers website that allows employees to review their employers. Employers are rated on nine dimensions including overall satisfaction, compensation and benefits, views of senior management, and business outlook. We track employee satisfaction scores to provide insights into the ability of these companies to attract and retain employees. CEO Approval and satisfaction with senior management scores are also important as they provide a view into how employees perceive their management and the direction of their company.

More Details

For our Glassdoor analyses, we focus on the reviews of current employees only. Filtering out the reviews of former employees is a proprietary approach that allows for a more robust analysis. It is not possible to map the review of a former employee to a distinct date – the employee could have left the company six months ago or six years ago. By removing the reviews of former employees, we resolve this date issue and are able to show rating trends over time.

To analyze these trends in ratings, UBS Evidence Lab aggregates review scores by year. For select companies and the competitive set, we can also create 90-day rolling averages of current employee ratings.

For many of the metrics such as **Overall Satisfaction, Compensation & Benefits, and Senior Management**, employees are asked to rate satisfaction scores on a 5-point scale. The score is an average of the responses.

For **Business Outlook**, employees who posted a review on Glassdoor were asked if Business Outlook over the next six months was getting better, getting worse, or staying the same. The business outlook metric is a diffusion index that is calculated based on the responses to that question and is the percentage of positive responses plus one half of the percentage of neutral responses. Values above 50 indicate that business outlook for the next six months is improving and values below 50 indicate that business outlook is getting worse.

For **CEO Approval**, employees were asked if they approve of the CEO, have no opinion of the CEO, or disapprove of the CEO. The CEO approval rating, as is the case for the Business Outlook rating, is also a diffusion index, which means it is reflective of the number of reviewers who approve of the CEO plus one half of the number of reviewers who have no opinion of the CEO, divided by the number of people who responded to the CEO approval question.

For this report, UBS analyzed current employee reviews from Glassdoor, a leading careers website, to measure trends in employee satisfaction metrics and CEO approval across 103 leading companies in US Semiconductor sector. UBS Evidence Lab used advanced web scraping techniques to collect over 30,000 current employee reviews. This report leverages the following UBS Evidence Lab asset: US Semiconductor Employee Reviews Monitor [Glassdoor]. The reviews are current through 10/21/19.

Valuation Method and Risk Statement

Valuations were not performed as part of this report. We use various methodologies such as EV/FCF, P/TBV, P/E for valuing companies in our coverage universe. Risk factors include but are not limited to macroeconomic factors such as a downturn in the economy, disruption of international trade, technological disruption due to new inventions, or business model innovation whereby structural changes in the industry alter the future course of unit sales, ASPs, and revenues.

Required Disclosures

This report has been prepared by UBS Securities LLC, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

For information on the ways in which UBS manages conflicts and maintains independence of its research product; historical performance information; and certain additional disclosures concerning UBS research recommendations, please visit www.ubs.com/disclosures. The figures contained in performance charts refer to the past; past performance is not a reliable indicator of future results. Additional information will be made available upon request. UBS Securities Co. Limited is licensed to conduct securities investment consultancy businesses by the China Securities Regulatory Commission. UBS acts or may act as principal in the debt securities (or in related derivatives) that may be the subject of this report. This recommendation was finalized on: 21 December 2019 03:25 PM GMT. UBS has designated certain Research department members as Derivatives Research Analysts where those department members publish research principally on the analysis of the price or market for a derivative, and provide information reasonably sufficient upon which to base a decision to enter into a derivatives transaction. Where Derivatives Research Analysts co-author research reports with Equity Research Analysts or Economists, the Derivatives Research Analyst is responsible for the derivatives investment views, forecasts, and/or recommendations.

Analyst Certification: Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner, including with respect to UBS, and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

UBS Investment Research: Global Equity Rating Definitions

12-Month Rating	Definition	Coverage ¹	IB Services ²
Buy	FSR is > 6% above the MRA.	45%	29%
Neutral	FSR is between -6% and 6% of the MRA.	40%	29%
Sell	FSR is > 6% below the MRA.	15%	21%
Short-Term Rating	Definition	Coverage ³	IB Services ⁴
Buy	Stock price expected to rise within three months from the time the rating was assigned because of a specific catalyst or event.	<1%	<1%
Sell	Stock price expected to fall within three months from the time the rating was assigned because of a specific catalyst or event.	<1%	<1%

Source: UBS. Rating allocations are as of 30 September 2019.

1:Percentage of companies under coverage globally within the 12-month rating category.

2:Percentage of companies within the 12-month rating category for which investment banking (IB) services were provided within the past 12 months.

3:Percentage of companies under coverage globally within the Short-Term rating category.

4:Percentage of companies within the Short-Term rating category for which investment banking (IB) services were provided within the past 12 months.

KEY DEFINITIONS: **Forecast Stock Return (FSR)** is defined as expected percentage price appreciation plus gross dividend yield over the next 12 months. In some cases, this yield may be based on accrued dividends. **Market Return Assumption (MRA)** is defined as the one-year local market interest rate plus 5% (a proxy for, and not a forecast of, the equity risk premium). **Under Review (UR)** Stocks may be flagged as UR by the analyst, indicating that the stock's price target and/or rating are subject to possible change in the near term, usually in response to an event that may affect the investment case or valuation. **Short-Term Ratings** reflect the expected near-term (up to three months) performance of the stock and do not reflect any change in the fundamental view or investment case. **Equity Price Targets** have an investment horizon of 12 months.

EXCEPTIONS AND SPECIAL CASES: UK and European Investment Fund ratings and definitions are: **Buy:** Positive on factors such as structure, management, performance record, discount; **Neutral:** Neutral on factors such as structure, management, performance record, discount; **Sell:** Negative on factors such as structure, management, performance record, discount. **Core Banding Exceptions (CBE):** Exceptions to the standard +/-6% bands may be granted by the Investment Review Committee (IRC). Factors considered by the IRC include the stock's volatility and the credit spread of the respective company's debt. As a result, stocks deemed to be very high or low risk may be subject to higher or lower bands as they relate to the rating. When such exceptions apply, they will be identified in the Company Disclosures table in the relevant research piece.

Research analysts contributing to this report who are employed by any non-US affiliate of UBS Securities LLC are not registered/qualified as research analysts with FINRA. Such analysts may not be associated persons of UBS Securities LLC and therefore are not subject to the FINRA restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account. The name of each affiliate and analyst employed by that affiliate contributing to this report, if any, follows.

UBS Securities LLC: Timothy Arcuri; Pradeep Ramani.

Company Disclosures

Company Name	Reuters	12-month rating	Short-term rating	Price	Price date
Advanced Micro Devices Inc ^{16, 20}	AMD.O	Neutral (CBE)		N/A	US\$44.15
Applied Materials Inc ^{16, 20}	AMAT.O	Sell (CBE)		N/A	US\$61.81
Broadcom Limited ¹⁶	AVGO.O	Buy		N/A	US\$319.00
Intel Corp. ^{4, 6a, 6b, 6c, 7, 16, 22}	INTC.O	Buy		N/A	US\$58.95
KLA Corporation ¹⁶	KLAC.O	Sell		N/A	US\$177.47
LAM Research Corp ¹⁶	LRCX.O	Sell		N/A	US\$297.41
Marvell Technology Group ¹⁶	MRVL.O	Buy		N/A	US\$25.96
Micron Technology Inc ¹⁶	MU.O	Neutral		N/A	US\$55.06
NVIDIA Corp ^{16, 22}	NVDA.O	Buy		N/A	US\$239.37
Qualcomm Inc. ^{3, 16}	QCOM.O	Neutral		N/A	US\$88.85
Texas Instruments Inc ¹⁶	TXN.O	Sell		N/A	US\$128.95
					20 Dec 2019

Source: UBS. All prices as of local market close.

Ratings in this table are the most current published ratings prior to this report. They may be more recent than the stock pricing date

- 3. UBS Securities LLC is acting as financial advisor to Elliott Advisors (UK) Limited in regards to its economic interest in NXP Semiconductors N.V. (NXP) and to NXP's definitive agreement to be acquired by Qualcomm Inc.
- 4. Within the past 12 months, UBS AG, its affiliates or subsidiaries has received compensation for investment banking services from this company/entity or one of its affiliates.
- 6a. This company/entity is, or within the past 12 months has been, a client of UBS Securities LLC, and investment banking services are being, or have been, provided.
- 6b. This company/entity is, or within the past 12 months has been, a client of UBS Securities LLC, and non-investment banking securities-related services are being, or have been, provided.
- 6c. This company/entity is, or within the past 12 months has been, a client of UBS Securities LLC, and non-securities services are being, or have been, provided.
- 7. Within the past 12 months, UBS Securities LLC and/or its affiliates have received compensation for products and services other than investment banking services from this company/entity.
- 16. UBS Securities LLC makes a market in the securities and/or ADRs of this company.
- 20. Because this security exhibits higher-than-average volatility, the FSR has been set at 15% above the MRA for a Buy rating, and at -15% below the MRA for a Sell rating (compared with +/-6% under the normal rating system).
- 22. UBS AG, its affiliates or subsidiaries held other significant financial interests in this company/entity as of last month's end (or the prior month's end if this report is dated less than 10 working days after the most recent month's end).

Unless otherwise indicated, please refer to the Valuation and Risk sections within the body of this report. For a complete set of disclosure statements associated with the companies discussed in this report, including information on valuation and risk, please contact UBS Securities LLC, 1285 Avenue of Americas, New York, NY 10019, USA, Attention: Investment Research.

The Disclaimer relevant to Global Wealth Management clients follows the Global Disclaimer.

Global Disclaimer

This document has been prepared by UBS Securities LLC, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

This Document is provided solely to recipients who are expressly authorized by UBS to receive it. If you are not so authorized you must immediately destroy the Document.

Global Research is provided to our clients through UBS Neo, and in certain instances, UBS.com and any other system or distribution method specifically identified in one or more communications distributed through UBS Neo or UBS.com (each a system) as an approved means for distributing Global Research. It may also be made available through third party vendors and distributed by UBS and/or third parties via e-mail or alternative electronic means. The level and types of services provided by Global Research to a client may vary depending upon various factors such as a client's individual preferences as to the frequency and manner of receiving communications, a client's risk profile and investment focus and perspective (e.g., market wide, sector specific, long-term, short-term, etc.), the size and scope of the overall client relationship with UBS and legal and regulatory constraints.

All Global Research is available on UBS Neo. Please contact your UBS sales representative if you wish to discuss your access to UBS Neo.

When you receive Global Research through a System, your access and/or use of such Global Research is subject to this Global Research Disclaimer and to the UBS Neo Platform Use Agreement (the "Neo Terms") together with any other relevant terms of use governing the applicable System.

When you receive Global Research via a third party vendor, e-mail or other electronic means, you agree that use shall be subject to this Global Research Disclaimer, the Neo Terms and where applicable the UBS Investment Bank terms of business (<https://www.ubs.com/global/en/investment-bank/regulatory.html>) and to UBS's Terms of Use/Disclaimer (<http://www.ubs.com/global/en/legalinfo2/disclaimer.html>). In addition, you consent to UBS processing your personal data and using cookies in accordance with our Privacy Statement (<http://www.ubs.com/global/en/legalinfo2/privacy.html>) and cookie notice (<http://www.ubs.com/global/en/homepage/cookies/cookie-management.html>).

If you receive Global Research, whether through a System or by any other means, you agree that you shall not copy, revise, amend, create a derivative work, provide to any third party, or in any way commercially exploit any UBS research provided via Global Research or otherwise, and that you shall not extract data from any research or estimates provided to you via Global Research or otherwise, without the prior written consent of UBS.

This document is for distribution only as may be permitted by law. It is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject UBS to any registration or licensing requirement within such jurisdiction.

This document is a general communication and is educational in nature; it is not an advertisement nor is it a solicitation or an offer to buy or sell any financial instruments or to participate in any particular trading strategy. Nothing in this document constitutes a representation that any investment strategy or recommendation is suitable or appropriate to an investor's individual circumstances or otherwise constitutes a personal recommendation. By providing this document, none of UBS or its representatives has any responsibility or authority to provide or have provided investment advice in a fiduciary capacity or otherwise. Investments involve risks, and investors should exercise prudence and their own judgment in making their investment decisions. None of UBS or its representatives is suggesting that the recipient or any other person take a specific course of action or any action at all. By receiving this document, the recipient acknowledges and agrees with the intended purpose described above and further disclaims any expectation or belief that the information constitutes investment advice to the recipient or otherwise purports to meet the investment objectives of the recipient. The financial instruments described in the document may not be eligible for sale in all jurisdictions or to certain categories of investors.

Options, structured derivative products and futures (including OTC derivatives) are not suitable for all investors. Trading in these instruments is considered risky and may be appropriate only for sophisticated investors. Prior to buying or selling an option, and for the complete risks relating to options, you must receive a copy of "The Characteristics and Risks of Standardized Options." You may read the document at <http://www.theocc.com/publications/risks/riskchap1.jsp> or ask your salesperson for a copy. Various theoretical explanations of the risks associated with these instruments have been published. Supporting documentation for any claims, comparisons, recommendations, statistics or other technical data will be supplied upon request. Past performance is not necessarily indicative of future results. Transaction costs may be significant in option strategies calling for multiple purchases and sales of options, such as spreads and straddles. Because of the importance of tax considerations to many options transactions, the investor considering options should consult with his/her tax advisor as to how taxes affect the outcome of contemplated options transactions.

Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates or other market conditions. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument referred to in the document. For investment advice, trade execution or other enquiries, clients should contact their local sales representative.

The value of any investment or income may go down as well as up, and investors may not get back the full (or any) amount invested. Past performance is not necessarily a guide to future performance. Neither UBS nor any of its directors, employees or agents accepts any liability for any loss (including investment loss) or damage arising out of the use of all or any of the Information.

Prior to making any investment or financial decisions, any recipient of this document or the information should take steps to understand the risk and return of the investment and seek individualized advice from his or her personal financial, legal, tax and other professional advisors that takes into account all the particular facts and circumstances of his or her investment objectives.

Any prices stated in this document are for information purposes only and do not represent valuations for individual securities or other financial instruments. There is no representation that any transaction can or could have been effected at those prices, and any prices do not necessarily reflect UBS's internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions by UBS or any other source may yield substantially different results.

No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained in any materials to which this document relates (the "Information"), except with respect to Information concerning UBS. The Information is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. UBS does not undertake to update or keep current the Information. Any opinions expressed in this document may change without notice and may differ or be contrary to opinions expressed by other business areas or groups, personnel or other representative of UBS. Any statements contained in this report attributed to a third party represent UBS's interpretation of the data, information and/or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party. In no circumstances may this document or any of the Information (including any forecast, value, index or other calculated amount ("Values")) be used for any of the following purposes:

- (i) valuation or accounting purposes;
- (ii) to determine the amounts due or payable, the price or the value of any financial instrument or financial contract; or
- (iii) to measure the performance of any financial instrument including, without limitation, for the purpose of tracking the return or performance of any Value or of defining the asset allocation of portfolio or of computing performance fees.

By receiving this document and the Information you will be deemed to represent and warrant to UBS that you will not use this document or any of the Information for any of the above purposes or otherwise rely upon this document or any of the Information.

UBS has policies and procedures, which include, without limitation, independence policies and permanent information barriers, that are intended, and upon which UBS relies, to manage potential conflicts of interest and control the flow of information within divisions of UBS and among its subsidiaries, branches and affiliates. For further information on the ways in which UBS manages conflicts and maintains independence of its research products, historical performance information and certain additional disclosures concerning UBS research recommendations, please visit www.ubs.com/disclosures.

Research will initiate, update and cease coverage solely at the discretion of UBS Research Management, which will also have sole discretion on the timing and frequency of any published research product. The analysis contained in this document is based on numerous assumptions. All material information in relation to published research reports, such as valuation methodology, risk statements, underlying assumptions (including sensitivity analysis of those assumptions), ratings history etc. as required by the Market Abuse Regulation, can be found on UBS Neo. Different assumptions could result in materially different results.

The analyst(s) responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting market information. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this document is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues; however, compensation may relate to the revenues of UBS and/or its divisions as a whole, of which investment banking, sales and trading are a part, and UBS's subsidiaries, branches and affiliates as a whole.

For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC) acts as a market maker or liquidity provider (in accordance with the interpretation of these terms under English law or, if not carried out by UBS in the UK the law of the relevant jurisdiction in which UBS determines it carries out the activity) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance with the definition given to it by the laws and regulations of any other EU jurisdictions, such information is separately disclosed in this document. For financial instruments admitted to trading on a non-EU regulated market: UBS may act as a market maker save that where this activity is carried out in the US in accordance with the definition given to it by the relevant laws and regulations, such activity will be specifically disclosed in this document. UBS may have issued a warrant the value of which is based on one or more of the financial instruments referred to in the document. UBS and its affiliates and employees may have long or short positions, trade as principal and buy and sell in instruments or derivatives identified herein; such transactions or positions may be inconsistent with the opinions expressed in this document.

Within the past 12 months UBS AG, its affiliates or subsidiaries may have received or provided investment services and activities or ancillary services as per MiFID II which may have given rise to a payment or promise of a payment in relation to these services from or to this company.

Where Global Research refers to "UBS Evidence Lab Inside" or has made use of data provided by UBS Evidence Lab you understand that UBS Evidence Lab is a separate department to Global Research and that UBS Evidence Lab does not provide research, investment recommendations or advice.

United Kingdom: This material is distributed by UBS AG, London Branch to persons who are eligible counterparties or professional clients. UBS AG, London Branch is authorised by the Prudential Regulation Authority and subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. **Europe:** Except as otherwise specified herein, these materials are distributed by UBS Europe SE, a subsidiary of UBS AG, to persons who are eligible counterparties or professional clients (as detailed in the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) Rules and according to MiFID) and are only available to such persons. The information does not apply to, and should not be relied upon by, retail clients. UBS Europe SE is authorised by the [European Central Bank (ECB)] and regulated by the BaFin and the ECB. **France:** Prepared by UBS Europe SE and distributed by UBS Europe SE and UBS Securities France S.A. UBS Securities France S.A. is regulated by the ACPR (Autorité de Contrôle Prudentiel et de Résolution) and the Autorité des Marchés Financiers (AMF). Where an analyst of UBS Securities France S.A. has contributed to this document, the document is also deemed to have been prepared by UBS Securities France S.A. **Germany, Luxembourg, the Netherlands, Belgium and Ireland:** Prepared by UBS AG, London Branch and distributed by UBS AG, London Branch and UBS Europe SE. **Spain:** Prepared by UBS Europe SE and distributed by UBS Europe SE and UBS Securities España SV, SA. UBS Securities España SV, SA is regulated by the Comisión Nacional del Mercado de Valores (CNMV). **Turkey:** Distributed by UBS AG, London Branch. No information in this document is provided for the purpose of offering, marketing and sale by any means of any capital market instruments and services in the Republic of Turkey. Therefore, this document may not be considered as an offer made or to be made to residents of the Republic of Turkey. UBS AG, London Branch is not licensed by the Turkish Capital Market Board under the provisions of the Capital Market Law (Law No. 6362). Accordingly, neither this document nor any other offering material related to the instruments/services may be utilized in connection with providing any capital market services to persons within the Republic of Turkey without the prior approval of the Capital Market Board. However, according to article 15 (d) (ii) of the Decree No. 32, there is no restriction on the purchase or sale of the securities abroad by residents of the Republic of Turkey. **Poland:** Distributed by UBS Europe SE (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce regulated by the Polish Financial Supervision Authority. Where an analyst of UBS Europe SE (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce has contributed to this document, the document is also deemed to have been prepared by UBS Europe SE (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce. **Russia:** Prepared and distributed by UBS Bank (OOO). **Switzerland:** Distributed by UBS AG to persons who are institutional investors only. UBS AG is regulated by the Swiss Financial Market Supervisory Authority (FINMA). **Italy:** Prepared by UBS Europe SE and distributed by UBS Europe SE and UBS Europe SE, Italy Branch. Where an analyst of UBS Europe SE, Italy Branch has contributed to this document, the document is also deemed to have been prepared by UBS Europe SE, Italy Branch. **South Africa:** Distributed by UBS South Africa (Pty) Limited (Registration No. 1995/011140/07), an authorised user of the JSE and an authorised Financial Services Provider (FSP 7328). **Israel:** This material is distributed by UBS AG, London Branch. UBS Securities Israel Ltd is a licensed Investment Marketer that is supervised by the Israel Securities Authority (ISA). UBS AG, London Branch and its affiliates incorporated outside Israel are not licensed under the Israeli Advisory Law. UBS AG, London Branch is not covered by insurance as required from a licensee under the Israeli Advisory Law. UBS may engage among others in issuance of Financial Assets or in distribution of Financial Assets of other issuers for fees or other benefits. UBS AG, London Branch and its affiliates may prefer various Financial Assets to which they have or may have Affiliation (as such term is defined under the Israeli Advisory Law). Nothing in this Material should be considered as investment advice under the Israeli Advisory Law. This Material is being issued only to and/or is directed only at persons who are Eligible Clients within the meaning of the Israeli Advisory Law, and this material must not be relied on or acted upon by any other persons. **Saudi Arabia:** This document has been issued by UBS AG (and/or any of its subsidiaries, branches or affiliates), a public company limited by shares, incorporated in Switzerland with its registered offices at Aeschenvorstadt 1, CH-4051 Basel and Bahnhofstrasse 45, CH-8001 Zurich. This publication has been approved by UBS Saudi Arabia (a subsidiary of UBS AG), a Saudi closed joint stock company incorporated in the Kingdom of Saudi Arabia under commercial register number 1010257812 having its registered office at Tatweer Towers, P.O. Box 75724, Riyadh 11588, Kingdom of Saudi Arabia. UBS Saudi Arabia is authorized and regulated by the Capital Market Authority to conduct securities business under license number 08113-37. **UAE / Dubai:** The information distributed by UBS AG Dubai Branch is only intended for Professional Clients and/or Market Counterparties, as classified under the DFSA rulebook. No other person should act upon this material/communication. The information is not for further distribution within the United Arab Emirates. UBS AG Dubai Branch is regulated by the DFSA in the DIFC. UBS is not licensed to provide banking services in the UAE by the Central Bank of the UAE, nor is it licensed by the UAE Securities and Commodities Authority. **United States:** Distributed to US persons by either UBS Securities LLC or by UBS Financial Services Inc., subsidiaries of UBS AG; or by a group, subsidiary or affiliate of UBS AG that is not registered as a US broker-dealer (a '**non-US affiliate**') to major US institutional investors only. UBS Securities LLC or UBS Financial Services Inc. accepts responsibility for the content of a document prepared by another non-US affiliate when distributed to US persons by UBS Securities LLC or UBS Financial Services Inc. All transactions by a US person in the securities mentioned in this document must be effected through UBS Securities LLC or UBS Financial Services Inc., and not through a non-US affiliate. UBS Securities LLC is not acting as a municipal advisor to any municipal entity or obligated person within the meaning of Section 15B of the Securities Exchange Act (the "Municipal Advisor Rule"), and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of the Municipal Advisor Rule. **Canada:** Distributed by UBS Securities Canada Inc., a registered investment dealer in Canada and a Member-Canadian Investor Protection Fund, or by another affiliate of UBS AG that is registered to conduct business in Canada or is otherwise exempt from registration. **Mexico:** This report has been distributed and prepared by UBS Casa de Bolsa, S.A. de C.V., UBS Grupo Financiero, an entity that is part of UBS Grupo Financiero, S.A. de C.V. and is a subsidiary of UBS AG. This document is intended for distribution to institutional or sophisticated investors only. Research reports only reflect the views of the analysts responsible for the reports. Analysts do not receive any compensation from persons or entities different from UBS Casa de Bolsa, S.A. de C.V., UBS Grupo Financiero, or different from entities belonging to the same financial group or business group of such. For Spanish translations of applicable disclosures, please go to www.ubs.com/disclosures. **Brazil:** Except as otherwise specified herein, this material is prepared by UBS Brasil CCTVM S.A. to persons who are eligible investors residing in Brazil, which are considered to be Investidores Profissionais, as designated by the applicable regulation, mainly the CVM Instruction No. 539 from the 13th of November 2013 (determines the duty to verify the suitability of products, services and transactions with regards to the client's profile). **Hong Kong:** Distributed by UBS Securities Asia Limited and/or UBS AG, Hong Kong Branch, which is incorporated in Switzerland with limited liability. Please contact local licensed/registered representatives of UBS Securities Asia Limited and/or UBS AG, Hong Kong Branch in respect of any matters arising from, or in connection with, the analysis or document. **Singapore:** Distributed by UBS Securities Pte. Ltd. [MCI (P) 009/09/2018 and Co. Reg. No.: 198500648C] or UBS AG, Singapore Branch. Please contact UBS Securities Pte. Ltd., an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110); or UBS AG, Singapore Branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Banking Act (Cap. 19) regulated by the Monetary Authority of Singapore, in respect of any matters arising from, or in connection with, the analysis or document. The recipients of this document represent and warrant that they are accredited and institutional investors as defined in the Securities and Futures Act (Cap. 289). **Japan:** Distributed by UBS Securities Japan Co., Ltd. to professional investors (except as otherwise permitted). Where this document has been prepared by UBS Securities Japan Co., Ltd., UBS Securities Japan Co., Ltd. is the author, publisher and distributor of the document. Distributed by UBS AG, Tokyo Branch to Professional Investors (except as otherwise permitted) in relation to foreign exchange and other banking businesses when relevant. **Australia:** Clients of UBS AG: Distributed by UBS AG (ABN 47 088 129 613 and holder of Australian Financial Services License No. 231087). Clients of UBS Securities Australia Ltd: Distributed by UBS Securities Australia Ltd (ABN 62 008 586 481 and holder of Australian Financial Services License No. 231098). This Document contains general information and/or general advice only and does not constitute personal financial product advice. As such, the Information in this document has been prepared without taking into account any investor's objectives, financial situation or needs, and investors should, before acting

on the Information, consider the appropriateness of the Information, having regard to their objectives, financial situation and needs. If the Information contained in this document relates to the acquisition, or potential acquisition of a particular financial product by a 'Retail' client as defined by section 761G of the Corporations Act 2001 where a Product Disclosure Statement would be required, the retail client should obtain and consider the Product Disclosure Statement relating to the product before making any decision about whether to acquire the product. The UBS Securities Australia Limited Financial Services Guide is available at: www.ubs.com/ecs-research-fsg.

New Zealand: Distributed by UBS New Zealand Ltd. UBS New Zealand Ltd is not a registered bank in New Zealand. You are being provided with this UBS publication or material because you have indicated to UBS that you are a "wholesale client" within the meaning of section 5C of the Financial Advisers Act 2008 of New Zealand (Permitted Client). This publication or material is not intended for clients who are not Permitted Clients (non-permitted Clients). If you are a non-permitted Client you must not rely on this publication or material. If despite this warning you nevertheless rely on this publication or material, you hereby (i) acknowledge that you may not rely on the content of this publication or material and that any recommendations or opinions in such this publication or material are not made or provided to you, and (ii) to the maximum extent permitted by law (a) indemnify UBS and its associates or related entities (and their respective Directors, officers, agents and Advisors) (each a 'Relevant Person') for any loss, damage, liability or claim any of them may incur or suffer as a result of, or in connection with, your unauthorised reliance on this publication or material and (b) waive any rights or remedies you may have against any Relevant Person for (or in respect of) any loss, damage, liability or claim you may incur or suffer as a result of, or in connection with, your unauthorised reliance on this publication or material.

Korea: Distributed in Korea by UBS Securities Pte. Ltd., Seoul Branch. This document may have been edited or contributed to from time to time by affiliates of UBS Securities Pte. Ltd., Seoul Branch. This material is intended for professional/institutional clients only and not for distribution to any retail clients.

Malaysia: This material is authorized to be distributed in Malaysia by UBS Securities Malaysia Sdn. Bhd (Capital Markets Services License No.: CMSL/A0063/2007). This material is intended for professional/institutional clients only and not for distribution to any retail clients.

India: Distributed by UBS Securities India Private Ltd. (Corporate Identity Number U67120MH1996PTC097299) 2/F, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai (India) 400051. Phone: +912261556000. It provides brokerage services bearing SEBI Registration Number: INZ000259830; merchant banking services bearing SEBI Registration Number: INM000010809 and Research Analyst services bearing SEBI Registration Number: INH000001204. UBS AG, its affiliates or subsidiaries may have debt holdings or positions in the subject Indian company/companies. Within the past 12 months, UBS AG, its affiliates or subsidiaries may have received compensation for non-investment banking securities-related services and/or non-securities services from the subject Indian company/companies. The subject company/companies may have been a client/clients of UBS AG, its affiliates or subsidiaries during the 12 months preceding the date of distribution of the research report with respect to investment banking and/or non-investment banking securities-related services and/or non-securities services. With regard to information on associates, please refer to the Annual Report at: http://www.ubs.com/global/en/about_ubs/investor_relations/annualreporting.html

Taiwan: Distributed by UBS Securities Pte. Ltd., Taipei Branch which is regulated by the Taiwan Securities and Futures Bureau. This documents contains general information and/or general advice only and does NOT constitute any "Recommendation" to clients for the covered companies or any companies mentioned in this document.

Indonesia: This report is being distributed by PT UBS Sekuritas Indonesia and is delivered by its licensed employee(s), including marketing/sales person, to its client. PT UBS Sekuritas Indonesia, having its registered office at Wisma GKBI, 22nd floor, JL. Jend. Sudirman, kav.28, Jakarta 10210, Indonesia, is a subsidiary company of UBS AG and licensed under Capital Market Law no. 8 year 1995, a holder of broker-dealer and underwriter licenses issued by the Capital Market and Financial Institution Supervisory Agency (now Otoritas Jasa Keuangan/OJK). PT UBS Sekuritas Indonesia is also a member of Indonesia Stock Exchange and supervised by Otoritas Jasa Keuangan (OJK). Neither this report nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens except in compliance with applicable Indonesian capital market laws and regulations. This report is not an offer of securities in Indonesia and may not be distributed within the territory of the Republic of Indonesia or to Indonesian citizens in circumstance which constitutes an offering within the meaning of Indonesian capital market laws and regulations.

The disclosures contained in research documents produced by UBS AG, London Branch or UBS Europe SE shall be governed by and construed in accordance with English law.

UBS specifically prohibits the redistribution of this document in whole or in part without the written permission of UBS and in any event UBS accepts no liability whatsoever for any redistribution of this document or its contents or the actions of third parties in this respect. Images may depict objects or elements that are protected by third party copyright, trademarks and other intellectual property rights. © UBS 2019. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.

Global Wealth Management Disclaimer

You receive this document in your capacity as a client of UBS Global Wealth Management. This publication has been distributed to you by UBS Switzerland AG (regulated by FINMA in Switzerland) or its affiliates ("UBS") with whom you have a banking relationship with. The full name of the distributing affiliate and its competent authority can be found in the country-specific disclaimer at the end of this document.

The date and time of the first dissemination of this publication is the same as the date and time of its publication.

Risk information:

You agree that you shall not copy, revise, amend, create a derivative work, provide to any third party, or in any way commercially exploit any UBS research, and that you shall not extract data from any research or estimates, without the prior written consent of UBS.

This document is for distribution only as may be permitted by law. It is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject UBS to any registration or licensing requirement within such jurisdiction.

This document is a general communication and is educational in nature; it is not an advertisement nor is it a solicitation or an offer to buy or sell any financial instruments or to participate in any particular trading strategy. Nothing in this document constitutes a representation that any investment strategy or recommendation is suitable or appropriate to an investor's individual circumstances or otherwise constitutes a personal recommendation. By providing this document, none of UBS or its representatives has any responsibility or authority to provide or have provided investment advice in a fiduciary capacity or otherwise. Investments involve risks, and investors should exercise prudence and their own judgment in making their investment decisions. None of UBS or its representatives is suggesting that the recipient or any other person take a specific course of action or any action at all. By receiving this document, the recipient acknowledges and agrees with the intended purpose described above and further disclaims any expectation or belief that the information constitutes investment advice to the recipient or otherwise purports to meet the investment objectives of the recipient. The financial instruments described in the document may not be eligible for sale in all jurisdictions or to certain categories of investors.

Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates or other market conditions. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument referred to in the document. For investment advice, trade execution or other enquiries, clients should contact their local sales representative.

The value of any investment or income may go down as well as up, and investors may not get back the full (or any) amount invested. Past performance is not necessarily a guide to future performance. Neither UBS nor any of its directors, employees or agents accepts any liability for any loss (including investment loss) or damage arising out of the use of all or any of the information (as defined below).

Prior to making any investment or financial decisions, any recipient of this document or the information should take steps to understand the risk and return of the investment and seek individualized advice from his or her personal financial, legal, tax and other professional advisors that takes into account all the particular facts and circumstances of his or her investment objectives.

Any prices stated in this document are for information purposes only and do not represent valuations for individual securities or other financial instruments. There is no representation that any transaction can or could have been effected at those prices, and any prices do not necessarily reflect UBS's internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions by UBS or any other source may yield substantially different results.

No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained in any materials to which this document relates (the "Information"), except with respect to Information concerning UBS. The Information is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. UBS does not undertake to update or keep current the Information. Any opinions expressed in this document may change without notice and may differ or be contrary to opinions expressed by other business areas or groups, personnel or other representative of UBS. Any statements contained in this report attributed to a third party represent UBS's interpretation of the data, information and/or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party. In no circumstances may this document or any of the Information (including any forecast, value, index or other calculated amount ("Values")) be used for any of the following purposes:

- (i) valuation or accounting purposes;
- (ii) to determine the amounts due or payable, the price or the value of any financial instrument or financial contract; or
- (iii) to measure the performance of any financial instrument including, without limitation, for the purpose of tracking the return or performance of any Value or of defining the asset allocation of portfolio or of computing performance fees.

By receiving this document and the Information you will be deemed to represent and warrant to UBS that you will not use this document or any of the Information for any of the above purposes or otherwise rely upon this document or any of the Information.

UBS has policies and procedures, which include, without limitation, independence policies and permanent information barriers, that are intended, and upon which UBS relies, to manage potential conflicts of interest and control the flow of information within divisions of UBS (including between Global Wealth Management and Research) and among its subsidiaries, branches and affiliates. For further information on the ways in which UBS manages conflicts and maintains independence of its research products, historical performance information and certain additional disclosures concerning UBS research recommendations, please visit www.ubs.com/disclosures.

Research will initiate, update and cease coverage solely at the discretion of research management, which will also have sole discretion on the timing and frequency of any published research product. The analysis contained in this document is based on numerous assumptions. Different assumptions could result in materially different results.

The analyst(s) responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting market information. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this document is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues; however, compensation may relate to the revenues of UBS and/or its divisions as a whole, of which investment banking, sales and trading are a part, and UBS's subsidiaries, branches and affiliates as a whole.

For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC) acts as a market maker or liquidity provider (in accordance with the interpretation of these terms in the UK) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance with the definition given to it by the laws and regulations of any other EU jurisdictions, such information is separately disclosed in this document. For financial instruments admitted to trading on a non-EU regulated market: UBS may act as a market maker save that where this activity is carried out in the US in accordance with the definition given to it by the relevant laws and regulations, such activity will be specifically disclosed in this document. UBS may have issued a warrant the value of which is based on one or more of the financial instruments referred to in the document. UBS and its affiliates and employees may have long or short positions, trade as principal and buy and sell in instruments or derivatives identified herein; such transactions or positions may be inconsistent with the opinions expressed in this document.

Within the past 12 months UBS Switzerland AG, its affiliates or subsidiaries may have received or provided investment services and activities or ancillary services as per MiFID II which may have given rise to a payment or promise of a payment in relation to these services from or to this company.

If you require detailed information on disclosures of interest or conflict of interest as required by Market Abuse Regulation please contact the mailbox MAR_disclosures_twopager@ubs.com. Please note that e-mail communication is unsecured.

External Asset Managers / External Financial Consultants: In case this research or publication is provided to an External Asset Manager or an External Financial Consultant, UBS expressly prohibits that it is redistributed by the External Asset Manager or the External Financial Consultant and is made available to their clients and/or third parties.

Distributed to US persons by UBS Financial Services Inc. or UBS Securities LLC, subsidiaries of UBS AG. UBS Switzerland AG, UBS Europe SE, UBS Bank, S.A., UBS Brasil Administradora de Valores Mobiliários Ltda, UBS Asesores Mexico, S.A. de C.V., UBS Securities Japan Co., Ltd, UBS Wealth Management Israel Ltd and UBS Menkul Degerler AS are affiliates of UBS AG. UBS Financial Services Incorporated of Puerto Rico is a subsidiary of UBS Financial Services Inc. **UBS Financial Services Inc. accepts responsibility for the content of a report prepared by a non-US affiliate when it distributes reports to US persons. All transactions by a US person in the securities mentioned in this report should be effected through a US-registered broker dealer affiliated with UBS, and not through a non-US affiliate. The contents of this report have not been and will not be approved by any securities or investment authority in the United States or elsewhere. UBS Financial Services Inc. is not acting as a municipal advisor to any municipal entity or obligated person within the meaning of Section 15B of the Securities Exchange Act (the "Municipal Advisor Rule") and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of the Municipal Advisor Rule.**

Austria: This publication is not intended to constitute a public offer under Austrian law. It is distributed only for information purposes to clients of UBS Europe SE, Niederlassung Österreich, with place of business at Wächtergasse 1, A-1010 Wien. UBS Europe SE, Niederlassung Österreich is subject to the joint supervision of the European Central Bank ("ECB"), the German Central Bank (Deutsche Bundesbank), the German Federal Financial Services Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), as well as of the Austrian Financial Market Authority (Finanzmarktaufsicht, FMA), to which this publication has not been submitted for approval. UBS Europe SE is a credit institution constituted under German law in the form of a Societas Europaea, duly authorized by the ECB. **Bahrain:** UBS is a Swiss bank not licensed, supervised or regulated in Bahrain by the Central Bank of Bahrain and does not undertake banking or investment business activities in Bahrain. Therefore, clients have no protection under local banking and investment services laws and regulations. **Canada:** The information contained herein is not, and under no circumstances is to be construed as, a prospectus, an advertisement, a public offering, an offer to sell securities described herein, solicitation of an offer to buy securities described herein, in Canada or any province or territory thereof. Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators and only by a dealer properly registered under applicable securities laws or, alternatively, pursuant to an exemption from the dealer registration requirement in the relevant province or territory of Canada in which such offer or sale is made. Under no circumstances is the information contained herein to be construed as investment advice in any province or territory of Canada and is not tailored to the needs of the recipient. To the extent that the information contained herein references securities of an issuer incorporated, formed or created under the laws of Canada or a province or territory of Canada, any trades in such securities must be conducted through a dealer registered in Canada or, alternatively, pursuant to a dealer registration exemption. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon these materials, the information contained herein or the merits of the securities described herein and any representation to the contrary is an offence. In Canada, this publication is distributed by UBS Investment Management Canada Inc. **China:** This research report is neither intended to be distributed to PRC investors nor to provide securities investment consultancy services within the territory of PRC. **Czech Republic:** UBS is not a licensed bank in the Czech Republic and thus is not allowed to provide regulated banking or investment services in the Czech Republic. Please notify UBS if you do not wish to receive any further correspondence. **Denmark:** This publication is not intended to constitute a public offer under Danish law. It is distributed only for information purposes to clients of UBS Europe SE, Denmark Branch, filial af UBS Europe SE, with place of business at Sankt Annae Plads 13, 1250 Copenhagen, Denmark, registered with the Danish Commerce and Companies Agency, under No. 38 17 24 33. UBS Europe SE, Denmark Branch, filial af UBS Europe SE is subject to the joint supervision of the European Central Bank ("ECB"), the German Central Bank (Deutsche Bundesbank), the German Federal Financial Services Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), as well as of the Danish Financial Supervisory Authority (Finanstilsynet), to which this publication has not been submitted for approval. UBS Europe SE is a credit institution constituted under German law in the form of a Societas Europaea, duly authorized by the ECB. **Egypt:** Securities or other investment products are not being offered or sold by UBS to the public in Egypt and they have not been and will not be registered with the Egyptian Financial Supervisory Authority. **France:** This publication is distributed by UBS (France) S.A., French "société anonyme" with share capital of € 132.975.556, 69, boulevard Haussmann F-75008 Paris, R.C.S. Paris B 421 255 670, to its clients and prospects. UBS (France) S.A. is a provider of investment services duly authorized according to the terms of the "Code Monétaire et Financier", regulated by French banking and financial authorities as the "Autorité de Contrôle Prudentiel et de Résolution." **Germany:** This publication is not intended to constitute a public offer under German law. It is distributed only for information purposes to clients of UBS Europe SE, Germany, with place of business at Bockenheimer Landstrasse 2-4, 60306 Frankfurt am Main. UBS Europe SE is a credit institution constituted under German law in the form of a Societas Europaea, duly authorized by the European Central Bank ("ECB"), and supervised by the ECB, the German Central Bank (Deutsche Bundesbank) and the German Federal Financial Services Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), to which this publication has not been submitted for approval. **Greece:** UBS Switzerland AG and its affiliates (UBS) are not licensed as bank or financial institution under Greek legislation and do not provide banking and financial services in Greece. Consequently, UBS provides such services from branches outside of Greece, only. This document may not be considered as a public offering made or to be made to residents of Greece. **Hong Kong:** This publication is distributed to clients of UBS AG Hong Kong Branch by UBS AG Hong Kong Branch, a licensed bank under the Hong Kong Banking Ordinance and a registered institution under the Securities and Futures Ordinance. UBS AG Hong Kong Branch is incorporated in Switzerland with limited liability. **Indonesia, Malaysia, Philippines, Thailand:** This material was provided to you as a result of a request received by UBS from you and/or persons entitled to make the request on your behalf. Should you have received the material erroneously, UBS asks that you kindly destroy/delete it and inform UBS immediately. Any and all advice provided and/or trades executed by UBS pursuant to the material will only have been provided upon your specific request or executed upon your specific instructions, as the case may be, and may be deemed as such by UBS and you. The

material may not have been reviewed, approved, disapproved or endorsed by any financial or regulatory authority in your jurisdiction. The relevant investments will be subject to restrictions and obligations on transfer as set forth in the material, and by receiving the material you undertake to comply fully with such restrictions and obligations. You should carefully study and ensure that you understand and exercise due care and discretion in considering your investment objective, risk appetite and personal circumstances against the risk of the investment. You are advised to seek independent professional advice in case of doubt. **India:** UBS Securities India Private Ltd. (Corporate Identity Number U67120MH1996PTC097299) 2/F, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai (India) 400051. Phone: +912261556000. It provides brokerage services bearing SEBI Registration Number INZ000259830; merchant banking services bearing SEBI Registration Number: INM000010809 and Research Analyst services bearing SEBI Registration Number: INH000001204. UBS AG, its affiliates or subsidiaries may have debt holdings or positions in the subject Indian company/companies. Within the past 12 months, UBS AG, its affiliates or subsidiaries may have received compensation for non-investment banking securities-related services and/or non-securities services from the subject Indian company/companies. The subject company/companies may have been a client/clients of UBS AG, its affiliates or subsidiaries during the 12 months preceding the date of distribution of the research report with respect to investment banking and/or non-investment banking securities-related services and/or non-securities services. With regard to information on associates, please refer to the Annual Report at: http://www.ubs.com/global/en/about_ubs/investor_relations/annualreporting.html. **Israel:** UBS is a premier global financial firm offering wealth management, asset management and investment banking services from its headquarters in Switzerland and its operations in over 50 countries worldwide to individual, corporate and institutional investors. In Israel, UBS Switzerland AG is registered as Foreign Dealer in cooperation with UBS Wealth Management Israel Ltd., a wholly owned UBS subsidiary. UBS Wealth Management Israel Ltd. is a Portfolio Manager licensee which engages also in Investment Marketing and is regulated by the Israel Securities Authority. This publication is intended for information only and is not intended as an offer to buy or solicitation of an offer. Furthermore, this publication is not intended as an investment advice and/or investment marketing and is not replacing any investment advice and/or investment marketing provided by the relevant licensee which is adjusted to each person needs. No action has been, or will be, taken in Israel that would permit an offering of the product(s) mentioned in this document or a distribution of this document to the public in Israel. In particular, this document has not been reviewed or approved by the Israeli Securities Authority. The products(s) mentioned in this document is/are being offered to a limited number of sophisticated investors who qualify as one of the investors listed in the first supplement to the Israeli Securities Law, 5728-1968. This document may not be reproduced or used for any other purpose, nor be furnished to any other person other than those to whom copies have been sent. Anyone who purchases the product(s) mentioned herein shall do so for its own benefit and for its own account and not with the aim or intention of distributing or offering the product(s) to other parties. Anyone who purchases the product(s) shall do so in accordance with its own understanding and discretion and after it has received any relevant financial, legal, business, tax or other advice or opinion required by it in connection with such purchase(s). The word "advice" and/or any of its derivatives shall be read and construed in conjunction with the definition of the term "investment marketing" as defined under the Israeli Regulation of Investment Advice, Investment Marketing and Portfolio Management Law, 1995. **Italy:** This publication is not intended to constitute a public offer under Italian law. It is distributed only for information purposes to clients of UBS Europe SE, Succursale Italia, with place of business at Via del Vecchio Politecnico, 3-20121 Milano. UBS Europe SE, Succursale Italia is subject to the joint supervision of the European Central Bank ("ECB"), the German Central Bank (Deutsche Bundesbank), the German Federal Financial Services Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), as well as of the Bank of Italy (Banca d'Italia) and the Italian Financial Markets Supervisory Authority (CONSOB - Commissione Nazionale per le Società e la Borsa), to which this publication has not been submitted for approval. UBS Europe SE is a credit institution constituted under German law in the form of a Societas Europaea, duly authorized by the ECB. **Jersey:** UBS AG, Jersey Branch, is regulated and authorized by the Jersey Financial Services Commission for the conduct of banking, funds and investment business. Where services are provided from outside Jersey, they will not be covered by the Jersey regulatory regime. UBS AG, Jersey Branch is a branch of UBS AG a public company limited by shares, incorporated in Switzerland whose registered offices are at Aeschenvorstadt 1, CH-4051 Basel and Bahnhofstrasse 45, CH 8001 Zurich. UBS AG, Jersey Branch's principal place business is 1, IFC Jersey, St Helier, Jersey, JE2 3BX. **Luxembourg:** This publication is not intended to constitute a public offer under Luxembourg law. It is distributed only for information purposes to clients of UBS Europe SE, Luxembourg Branch, with place of business at 33A, Avenue J. F. Kennedy, L-1855 Luxembourg. UBS Europe SE, Luxembourg Branch is subject to the joint supervision of the European Central Bank ("ECB"), the German Central bank (Deutsche Bundesbank), the German Federal Financial Services Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), as well as of the Luxembourg supervisory authority (Commission de Surveillance du Secteur Financier), to which this publication has not been submitted for approval. UBS Europe SE is a credit institution constituted under German law in the form of a Societas Europaea, duly authorized by the ECB. **Mexico:** This information is distributed by UBS Asesores México, S.A. de C.V. ("UBS Asesores"), an affiliate of UBS Switzerland AG, incorporated as a non-independent investment advisor under the Securities Market Law due to the relation with a Foreign Bank. UBS Asesores is a regulated entity and it is subject to the supervision of the Mexican Banking and Securities Commission ("CNBV"), which exclusively regulates UBS Asesores regarding the rendering of portfolio management, as well as on securities investment advisory services, analysis and issuance of individual investment recommendations, so that the CNBV has no surveillance faculties nor may have over any other service provided by UBS Asesores. UBS Asesores is registered before CNBV under Registry number 30060. You are being provided with this UBS publication or material because you have indicated to UBS Asesores that you are a Sophisticated Qualified Investor located in Mexico. The compensation of the analyst(s) who prepared this report is determined exclusively by research management and senior management of any entity of UBS Group to which such analyst(s) render services. **Nigeria:** UBS Switzerland AG and its affiliates (UBS) are not licensed, supervised or regulated in Nigeria by the Central Bank of Nigeria or the Nigerian Securities and Exchange Commission (SEC) and do not undertake banking or investment business activities in Nigeria. The investment products mentioned in this material are not being offered or sold by UBS to the public in Nigeria and they have not been submitted for approval nor registered with the Nigerian SEC. If you are interested in products of this nature, please let us know and we will direct you to someone who can advise you. The investment products mentioned in this material are not being directed to, and are not being made available for subscription by any persons within Nigeria other than the selected investors to whom the offer materials have been addressed as a private sale or domestic concern within the exemption and meaning of Section 69(2) of the Investments and Securities Act, 2007 (ISA). **Portugal:** UBS Switzerland AG is not licensed to conduct banking and financial activities in Portugal nor is UBS Switzerland AG supervised by the Portuguese regulators (Bank of Portugal "Banco de Portugal" and Portuguese Securities Exchange Commission "Comissão do Mercado de Valores Mobiliários"). **Russia:** This document or information contained therein is for information purposes only and constitute neither a public nor a private offering, is not an invitation to make offers, to sell, exchange or otherwise transfer any financial instruments in the Russian Federation to or for the benefit of any Russian person or entity and does not constitute an advertisement or offering of securities in the Russian Federation within the meaning of Russian securities laws. **Singapore:** This material was provided to you as a result of a request received by UBS from you and/or persons entitled to make the request on your behalf. Should you have received the material erroneously, UBS asks that you kindly destroy/delete it and inform UBS immediately. Clients of UBS AG Singapore branch are asked to please contact UBS AG Singapore branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Banking Act (Cap. 19) regulated by the Monetary Authority of Singapore, in respect of any matters arising from, or in connection with, the analysis or report. **Spain:** This publication is not intended to constitute a public offer under Spanish law. It is distributed only for information purposes to clients of UBS Europe SE, Sucursal en España, with place of business at Calle María de Molina 4, C.P. 28006, Madrid. UBS Europe SE, Sucursal en España is subject to the joint supervision of the European Central Bank ("ECB"), the German Central bank (Deutsche Bundesbank), the German Federal Financial Services Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), as well as of the Spanish supervisory authority (Banco de España), to which this publication has not been submitted for approval. Additionally it is authorized to provide investment services on securities and financial instruments, regarding which it is supervised by the Comisión Nacional del Mercado de Valores as well. UBS Europe SE, Sucursal en España is a branch of UBS Europe SE, a credit institution constituted under German law in the form of a Societas Europaea, duly authorized by the ECB. **Sweden:** This publication is not intended to constitute a public offer under Swedish law. It is distributed only for information purposes to clients of UBS Europe SE, Sweden Bankfilial, with place of business at Regeringsgatan 38, 11153 Stockholm, Sweden, registered with the Swedish Companies Registration Office under Reg. No 516406-1011. UBS Europe SE, Sweden Bankfilial is subject to the joint supervision of the European Central Bank ("ECB"), the German Central bank (Deutsche Bundesbank), the German Federal Financial Services Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), as well as of the Swedish supervisory authority (Finansinspektionen), to which this publication has not been submitted for approval. UBS Europe SE is a credit institution constituted under German law in the form of a Societas Europaea, duly authorized by the ECB. **Taiwan:** This material is provided by UBS AG, Taipei Branch in accordance with laws of Taiwan, in agreement with or at the request of clients/prospects. **Turkey:** No information in this document is provided for the purpose of offering, marketing and sale by any means of any capital market instruments and services in the Republic of Turkey. Therefore, this document may not be considered as an offer made or to be made to residents of the Republic of Turkey in the Republic of Turkey. UBS Switzerland AG is not licensed by the Turkish Capital Market Board (the CMB) under the provisions of the Capital Market Law (Law No. 6362). Accordingly neither this document nor any other offering material related to the instruments/services may be utilized in connection with providing any capital market services to persons within the Republic of Turkey without the prior approval of the CMB. However, according to article 15 (d) (ii) of the Decree No. 32 there is no restriction on the purchase or sale of the instruments by residents of the Republic of Turkey. **UAE:** UBS is not licensed in the UAE by the Central Bank of UAE or by the Securities & Commodities Authority. The UBS AG Dubai Branch is licensed in the DIFC by the Dubai Financial Services Authority as an authorised firm. **United Kingdom:** This document is issued by UBS Wealth Management, a division of UBS AG which is authorised and regulated by the Financial Market Supervisory Authority in Switzerland. In the United Kingdom, UBS AG is authorised by the Prudential Regulation Authority and is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of regulation by the Prudential Regulation Authority are available from us on request. A member of the London Stock Exchange. This publication is distributed to retail clients of UBS Wealth Management. **Ukraine:** UBS is not registered and licensed as a bank/financial institution under Ukrainian legislation and does not provide banking and other financial services in Ukraine. UBS has not made and will not make any offer of the mentioned products to the public in Ukraine. No action has been taken to authorize an offer of the mentioned products to the public in Ukraine and the distribution of this document shall not constitute financial services for the purposes of the Law of Ukraine "On Financial Services and State Regulation of Financial Services Markets" dated 12 July 2001. Accordingly, nothing in this document or any other document, information or communication related to the mentioned products

shall be interpreted as containing an offer or invitation to offer, or solicitation of securities in the territory of Ukraine. Electronic communication must not be considered as an offer to enter into an electronic agreement or electronic instrument within the meaning of the Law of Ukraine "On Electronic Commerce" dated 3 September 2015.

This document is strictly for private use by its holder and may not be passed on to third parties or otherwise publicly distributed.

© UBS 2019. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.



尖峰报告社群

分享8万+行业报告/案例、7000+工具/模版；
精选各行业前沿数据、经典案例、职场干货等。



截屏本页，微信扫一扫或搜索公众号“尖峰报告”
回复<进群>即刻加入